Check for updates

OPEN ACCESS

EDITED BY Jian Ma, Harbin Medical University, China

REVIEWED BY Jiakun Lu, University of California, Los Angeles, United States Wei Sun, University of Michigan, United States Yuning Shen, University of Michigan, United States

*CORRESPONDENCE Shufa Li Shufali@qdu.edu.cn Xiuxing Jiang jxx0521@tmmu.edu.cn

[†]These authors have contributed equally to this work and share first authorship

RECEIVED 28 January 2024 ACCEPTED 20 May 2024 PUBLISHED 05 June 2024

CITATION

Guo H, Wan C, Zhu J, Jiang X and Li S (2024) Association of systemic immuneinflammation index with insulin resistance and prediabetes: a cross-sectional study. *Front. Endocrinol.* 15:1377792. doi: 10.3389/fendo.2024.1377792

COPYRIGHT

© 2024 Guo, Wan, Zhu, Jiang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Association of systemic immuneinflammation index with insulin resistance and prediabetes: a cross-sectional study

Han Guo^{1†}, Chuan Wan^{1†}, Jingjing Zhu¹, Xiuxing Jiang^{2*} and Shufa Li^{1*}

¹Department of Endocrinology and Metabolism, The Affiliated Hospital of Qingdao University, Qingdao, China, ²Frontier Medical Training Brigade, Third Military Medical University (Army Medical University), Xinjiang, China

Background and Objective: Previous research suggested a relationship between the Systemic Immune-Inflammation Index (SII) and multiple adverse health conditions. However, the role of SII in prediabetes and insulin resistance (IR) remains poorly understood. Therefore, this study aims to explore the potential relationship between SII and prediabetes and IR, providing data support for effective diabetes prevention by reducing systemic inflammation.

Methods: Linear regression models were used to assess the correlation between continuous SII and risk markers for type 2 diabetes (T2D). Subsequently, multivariate logistic regression models and subgroup analyses were employed to evaluate the association between SII tertiles and prediabetes and IR, controlling for various confounding factors. Finally, restricted cubic spline graphs were used to analyze the nonlinear relationship between SII and IR and prediabetes.

Results: After controlling for multiple potential confounders, SII was positively correlated with fasting blood glucose (FBG) (β : 0.100; 95% CI: 0.040 to 0.160), fasting serum insulin (FSI) (β : 1.042; 95% CI: 0.200 to 1.885), and homeostasis model assessment of insulin resistance (HOMA-IR) (β : 0.273; 95% CI: 0.022 to 0.523). Compared to participants with lower SII, those in the highest tertile had increased odds of prediabetes (OR: 1.17; 95% CI: 1.02-1.34; p for trend < 0.05) and IR (OR: 1.35; 95% CI: 1.18 to 1.51; p for trend<0.001).

Conclusions: Our study results demonstrate an elevated association between SII levels and both IR and prediabetes, indicating SII as a straightforward and cost-effective method identifying individuals with IR and prediabetes.

KEYWORDS

systemic immune-inflammation index, insulin resistance, prediabetes, cross-sectional study, NHANES

Introduction

Type 2 diabetes (T2D) poses a significant global public health challenge, profoundly affecting human health and quality of life (1). Prediabetes and insulin resistance (IR) stand out as primary contributors to T2D development, characterized by aberrant glucose metabolism (2). IR is a pivotal factor in various metabolic disorders, signifying a state where insulin-responsive tissues exhibit reduced responsiveness to physiological insulin levels. This state results in hyperinsulinemia and elevated fasting blood glucose (FBG), diagnostic indicators of IR (3). Despite being the gold standard for assessing IR, the hyperinsulinemic-euglycemic clamp is a costly, intrusive, and time-consuming procedure that needs to be performed by skilled staff. Therefore, the homeostasis model assessment of insulin resistance (HOMA-IR) offers a more straightforward and useful option by measuring insulin and fasting blood glucose (4).

IR is not only a key pathogenic factor in T2D but is also associated with various pathological conditions such as cardiovascular diseases, certain types of cancer, infertility, polycystic ovary syndrome, non-alcoholic fatty liver disease, and metabolic syndrome (5). Given the substantial harm that IR and prediabetes inflicts on human health, the early detection and intervention of them are hot topics among scholars in the relevant field. Previous research indicates that systemic chronic inflammation plays a pivotal role in IR and prediabetes, with obesity frequently triggering this inflammatory state (6). Obesity can induce a chronic inflammatory state in various insulin-target tissues, including adipose tissue, liver, muscles, and the pancreas. This is often attributed to potential interactions between immune processes and metabolic defects (7). Metabolic tissues induce the occurrence of this chronic low-grade inflammation by recruiting, accumulating, and activating pro-inflammatory macrophages. Although macrophages play a central role, other immune cell types are involved in these inflammatory processes (8). Satoshi discovered that CD8+ T cells can activate macrophages within adipose tissue. This alteration of the immune microenvironment leads to the shift of adipose tissue from an antiinflammatory state to a pro-inflammatory state (9). Hence, controlling inflammation seems to be a pivotal intervention for mitigating IR and prediabetes. Nevertheless, studies on the population-level association between inflammation and IR and prediabetes are still limited. A comprehensive exploration of this potential connection necessitates an urgently required objective assessment indicator that precisely mirrors the immune and inflammatory status of populations with IR and prediabetes.

The systemic immune-inflammation index (SII), developed by Hu et al., is a novel, comprehensive biomarker for immune inflammation based on blood cells (10). It integrates three types of inflammatory cells-platelets, neutrophils, and lymphocytes. It accurately reflects the local immune response and systemic inflammatory status of body (11). Multiple studies have substantiated the prognostic value of SII in assessing outcomes for various cancer patients, encompassing bladder cancer (12), cervical cancer (11), non-small cell lung cancer (13), colorectal cancer (14), and gastric cancer (15). In recent years, SII has emerged as an indicator for detecting chronic inflammatory disease beyond tumors. Yang et al. reported that in patients with coronary artery disease after coronary intervention, SII demonstrates superior predictive value for major cardiovascular events compared to traditional risk factors (16). Wang et al. suggested using SII as an indicator for detecting diabetes depression (17). Additionally, several studies utilizing the NHANES database reveal a robust association between SII and various metabolic diseases, such as diabetic nephropathy (18), hepatic steatosis (19), and osteoporosis (20). Moreover, numerous studies indicate that, compared to traditional immune-inflammatory indicators [including lymphocyte/monocyte ratio (LMR), platelet/lymphocyte ratio (NLR)], SII is a more accurate predictor of malignant tumors (21, 22).

In summary, SII is a non-invasive quantitative indicator with higher research value compared to traditional inflammatory markers. Given the relationship between inflammation and IR as well as prediabetes, we hypothesize that a high SII level may be positively associated with the risk of developing IR and prediabetes. However, research in this field is currently limited. Therefore, this study plans to employ the NHANES database for a more rigorous statistical analysis methods, controlling confounding variables to validate this hypothesis. Our goal is to identify individuals at high risk of IR through SII and explore the association between SII and markers of T2D risk. This will help investigate its potential to identify prediabetic patients.

Materials and methods


Data source and study sample

The National Health and Nutrition Examination Survey (NHANES), conducted by the National Center for Health Statistics (NCHS), is a nationwide survey assessing the health and nutritional status of adults and children in the United States. It employs a cross-sectional, multi-stage, stratified, and sub-group probability sampling design, with a two-year cycle (23). The survey covers various aspects, including in-home face-to-face interviews (demographics, socioeconomic status, diet, and health-related questions), as well as health examinations conducted at Mobile Examination Centers (MEC) collecting medical data, anthropometry, and laboratory tests (24). The NHANES protocol is revised and approved by the NCHS Ethics Review Committee, and all participants provide written informed consent (25).

The population data used in this cross-sectional study are from the NHANES database, covering seven consecutive periods (2005-2006, 2007-2008, 2009-2010, 2011-2012, 2013-2014, 2015-2016, and 2017-2018). It involves 60,936 participants, consistent with the results of Liu, et al. (26). We excluded pregnant participants, those under 18, potential type 1 diabetes patients (defined as those <20 years receiving only insulin treatment), and T2D patients (self-reported diabetes, insulin or oral hypoglycemic medication use, HbA1c (\geq 6.5%), fasting blood glucose (\geq 126 mg/ dL), or impaired glucose tolerance (\geq 200 mg/dL) (27), along with patients using various medications that may affect insulin sensitivity or with missing data (independent, dependent, and covariate data) (28). Finally, the study included 9,250 participants with complete data (Figure 1).

Exposure variable and outcome variables

The exposure variable is SII, calculated as platelet count × neutrophil count/lymphocyte count (29). Subsequently, participants were divided into three groups based on the tertiles of SII, namely Tertile 1 ($1.53 \le SII < 356.6$), Tertile 2 ($356.67 \le SII < 552.75$), and Tertile 3 ($SII \ge 552.75$). Outcome variables include risk markers for IR, prediabetes, and T2D, such as fasting blood glucose (FBG), glycated hemoglobin (HbA1c), fasting serum insulin (FSI), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). The formula for calculating HOMA-IR is [FBG × FSI/22.5] (30). In this study, HOMA-IR>2.6 is considered the diagnostic criterion for IR (31). Prediabetes is defined based on questionnaire and laboratory tests, with HbA1c levels between 5.7% and 6.4% or impaired fasting glucose levels (100-125 mg/dL) and/or impaired glucose tolerance (140-199 mg/dL) (32).



Covariates

Provided participants with standardized questionnaires to collect sociodemographic and lifestyle information. Based on previous research, we included covariates related to metabolic health risk factors, including low socioeconomic status, smoking status, alcohol consumption, physical activity, systolic blood pressure (SBP), diastolic blood pressure (DBP), body mass index (BMI), total cholesterol (TC), serum triglycerides (TG), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyltransferase (γ -GGT), alkaline phosphatase (ALP), serum creatinine (Cr), and lactate dehydrogenase (LDH). This study also included gender (male or female), age as a continuous variable or categorical variable (18-39 years, 40-59 years, or ≥60 years), race/ethnicity (non-Hispanic Black, other Hispanic, non-Hispanic White, or other race), education level (less than high school, high school, and beyond high school), PIR (categorized as 1, 1-2, 2-4, and >4), smoking status categorized as never smoked (before the survey<100 cigarettes), former smoker (smoked >100 cigarettes before the survey but quit before the survey), and current smoker (smoked >100 cigarettes before the survey and smoked during the survey) (33). Participants who consumed at least 12 drinks of any type of alcoholic beverage (12 ounces of beer, 5 ounces of wine, or 1.5 ounces of distilled spirits) within the past year were classified as drinkers (34). MVPA was defined as completing at least 10 minutes of vigorous/moderate-intensity physical activity in a typical week (2007-2018 cycle), resulting in substantial sweating, or a significant increase in breathing or heart rate (35).

Statistical analysis

In the description of the study population, continuous variables, if normally distributed, are presented as the mean with standard deviation; if skewed, they are presented as the median (25th-75th percentile). Both the normally and skewed distributed variables are analyzed using weight linear regression. Categorical variables are expressed as percentages and analyzed using the weighted chisquare test. We first established three weighted multivariable linear regression models to analyze the correlation between SII and T2D risk markers (FBG, HbA1c, FSI, and HOMA-IR). Model 1 was unadjusted for any covariates, Model 2 adjusted for covariates including age, gender, race, smoking and drinking status, PIR, education level, and physical activity status, and Model 3 adjusted for age, gender, race, smoking and drinking status, PIR, education level, physical activity status, BMI, TC, TG, ALT, AST, *y*-GGT, ALP, Cr, and LDH. Subsequently, to evaluate the association between continuous LgSII and participants stratified into three tertiles and IR and prediabetes, we conducted a multifactorial logistic regression. Afterward, subgroup analyses were performed to test for interaction and control of confounding categorical variables, including age (18-39 years, 40-59 years, or ≥ 60 years), gender, race, education level, PIR, smoking status, alcohol consumption, and MVPA. Subgroup analyses used weighted multifactorial logistic regression. These stratification variables were also considered predefined effect-modifying factors. To examine the heterogeneity

of associations between subgroups, interaction terms were introduced. Finally, we used Restricted Cubic Spline (RCS) regression to examine the non-linear relationship between SII and IR and prediabetes. Likelihood ratio tests were employed to confirm this relationship. It is noteworthy that, during regression analysis, SII was log-transformed as it exhibited a right-skewed distribution. All analyses were conducted using R software (version 4.1.2).

Results

Baseline characteristics of the study population

Table 1 presents the baseline characteristics of participants categorized by SII status. The study comprised 9250 participants, including 4827 males and 4423 females, with a median age of 45

TABLE 1 Basic characteristics	of the study population	(n=9250) in the NHANES.
-------------------------------	-------------------------	-------------------------

Variables	Overall	Tertile 1	Tertile 2	Tertile 3	P value
Categorical variables l%	(No.)				
Gender					<0.001
Male	52.18 (4827)	56.24 (1874)	50.94 (1686)	45.79 (1521)	
Female	47.82 (4423)	43.76 (1450)	49.06 (1624)	54.21 (1801)	
Race/Ethnicity					<0.001
Mexican American	15.32 (1417)	14.77 (492)	16.71 (553)	14.09 (468)	
Other Hispanic	9.33 (863)	8.34 (278)	9.85 (326)	9.30 (309)	
Non-Hispanic White	47.48 (4392)	39.41 (1313)	48.79 (1615)	55.75 (1852)	
Non-Hispanic Black	18.36 (1698)	26.05 (868)	15.29 (506)	13.46 (447)	
Other Races	9.51 (880)	11.43 (381)	9.37 (310)	7.41 (246)	
Education levels					0.003
Less than high school	22.96 (2124)	22.69 (756)	23.26 (770)	24.02 (798)	
High school diploma	23.29 (2154)	23.50 (783)	21.33 (706)	25.05 (832)	
More than high school	53.75 (4972)	53.81 (1973)	55.41 (1834)	50.93 (1692)	
PIR					0.032
<1	20.56 (1902)	21.01 (700)	19.58 (648)	21.70 (721)	
1-2	25.22 (2333)	25.39 (846)	24.92 (825)	26.31 (874)	
2-4	27.26 (2522)	26.98 (899)	26.92 (891)	27.36 (909)	
>4	26.95 (2493)	26.62 (887)	28.58 (946)	24.62 (818)	
MVPA	76.94 (7117)	78.69 (2622)	78.43 (2596)	71.88 (2388)	<0.001
Alcohol consumption	73.99 (6844)	72.42 (2413)	73.93 (2447)	73.90 (2455)	0.279
Smoking status					<0.001
Current smoker	21.69 (2006)	19.00 (633)	19.61 (649)	26.34 (875)	
Non-smoker	55.10 (5097)	57.86 (1928)	56.62 (1874)	49.16 (1633)	
Former smoker	23.21 (2147)	23.14 (771)	23.78 (787)	24.50 (814)	
Insulin resistance					<0.001
Yes	43.11 (3988)	40.15 (1335)	43.22 (1427)	48.07 (1595)	
No	56.89 (5262)	59.85 (1990)	56.78 (1875)	51.93 (1723)	
Continuous [Mean <u>+</u> SD	, Median (IQR)]				
Age (years)	45.00 (32.00-61.00)	44.00 (30.00-60.00)	44.00 (32.00-60.00)	47.00 (34.00-63.00)	<0.001
BMI (kg/m ²)	28.38 (± 6.56)	27.58 (± 5.91)	28.45 (±6.26)	29.14 (± 7.35)	<0.001

(Continued)

Variables	Overall	Tertile 1	Tertile 2	Tertile 3	P value
Continuous [Mean ± SD, M	ledian (IQR)]				
ALT (U/L)	21.00 (16.00-28.00)	21.00 (17.00-29.00)	21.00 (16.00-29.00)	20.00 (16.00-27.00)	<0.001
AST (U/L)	20.00 (23.00-28.00)	24.00 (20.00-28.00)	23.00 (20.00-28.00)	22.00 (19.00-27.00)	<0.001
Glycohemoglobin (%)	5.45 (± 0.47)	5.45 (± 0.47)	5.43 (± 0.45)	5.48 (± 0.48)	0.009
TC (mmol/L)	5.03 (±1.05)	4.96 (±1.05)	5.08 (± 1.05)	5.05 (± 1.04)	<0.001
TG (mmol/L)	1.12 (0.77-1.66)	1.03 (0.72-1.59)	1.14 (0.79-1.69)	1.16 (0.81-1.69)	<0.001
SBP (mmHg)	122.57 (±17.84)	122.14 (± 17.83)	121.97 (±17.50)	123.63 (±18.13)	0.001
DBP (mmHg)	69.39 (± 12.77)	69.35 (± 12.19)	69.54 (± 12.51)	69.27 (±13.59)	0.810
Gamma glutamyl transferase (U/L)	19.00 (14.00-29.00)	19.00 (14.00-29.00)	19.00 (14.00-29.00)	19.00 (14.00-30.00)	0.152
Alkaline phosphotase (U/L)	68.02 (± 22.57)	65.70 (±22.95)	67.36 (±21.12)	71.04 (± 23.27)	<0.001
Lactate dehydrogenase (U/L)	128.62 (± 32.05)	128.83 (± 37.81)	127.59 (±26.45)	129.45 (± 30.70)	0.462
Chloride (mmol/L)	104.13 (± 2.73)	104.20 (± 2.61)	104.19 (± 2.71)	103.99 (± 2.87)	0.003
Creatinine (µmol/L)	75.14 (63.65-88.40)	76.91 (65.20-88.40)	73.37 (62.76-87.52)	73.37 (61.88-88.40)	0.005
Fasting Glucose (mmol/L)	5.57 (±0.76)	5.52 (±0.73)	5.57 (± 0.76)	5.62 (±0.78)	<0.001
Insulin (µU/mL)	9.31 (5.98-14.96)	8.77 (5.64-14.15)	9.27 (6.00-14.92)	10.02 (6.34-16.05)	<0.001
HOMA-IR	2.13 (1.34-3.55)	2.27 (1.41-3.85)	2.49 (1.49-4.12)	2.51 (1.49-4.19)	<0.001

TABLE 1 Continued

Mean ± SD for continuous variables. The percentage (95% CI) for categorical variables.

SII, Systemic Immune-Inflammation Index; PIR, poverty income ratio; BMI, body mass index; MVPA, moderate/vigorous physical activity; SBP, systolic blood pressure; DBP, diastolic blood pressure; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TC, total cholesterol; TG, triglycerides.

years. Among them, 43.11% were diagnosed with IR, and 19.7% were considered to have prediabetes. Participants were divided into groups based on SII tertiles: Tertile 1 represented the relatively lower SII group (1.53≤SII<356.67); Tertile 2 represented the relatively higher SII group (356.67≤SII<552.75); Tertile 3 represented the highest SII group (SII≥552.75). Compared to those in the lower SII group, subjects in SII Tertile 3 included more females, fewer non-Hispanic Blacks, more current or former smokers, individuals with lower educational attainment, and those engaged in less physical activity. Across the three SII groups, significant differences were observed in BMI, FBG, HbA1c, FSI, HOMA-IR, TC, TG, ALT, AST, chloride, SBP, alkaline phosphatase, and creatinine levels (all P values <0.05). Importantly, individuals with higher SII levels had a higher proportion of prediabetes and IR patients (P<0.05 in both cases).

Association between SII and T2D risk markers

The correlation between SII and the risk markers of T2D was showed in Table 2. After adjusting for potential confounders, a significant correlation was observed between continuous SII and FBG, FSI, and HOMA-IR, while the relationship between SII and HbA1c was significant only when no covariates were adjusted. Following comprehensive adjustment for covariates in Model 3, participants in the second or third tertiles of SII had higher levels of FBG, FSI, and HOMA-IR compared to those in the first tertile. And the corresponding β coefficients (95% CI) for the highest tertile of SII were 0.048 (95% CI: 0.014 to 0.082), 0.658 (95% CI: 0.175 to 1.141), and 0.165 (95% CI: 0.021 to 0.309) for FBG, FSI, and HOMA-IR, respectively.

Relationship between SII and IR

As shown in Table 3, a significant positive correlation between SII and IR was demonstrated in the unadjusted original model (Model 1) (odds ratio=1.73; 95% confidence interval (CI), 1.45-2.06; P<0.001) and in the minimally adjusted model (Model 2) (OR=1.89; 95% CI: 1.57-2.28; P<0.001). Even after adjusting for all covariates (Model 3), this positive correlation persisted (OR=1.64; 95% CI: 1.32-2.04; P<0.001). This implies that for every one-unit increase in LgSII, the risk of IR increases by 64%. We further transformed SII from a continuous variable to a categorical variable (tertiles) for sensitivity analysis. Compared to participants in the lowest Tertile 1 group of SII, those in the highest Tertile 3 group had a 34% increased risk of IR, with statistical significance (OR=1.34; 95% CI: 1.18-1.51; P<0.001). Although participants in the Tertile 2 group also exhibited a higher risk of IR compared to the Tertile 1 group, with a 4% increased risk, but this difference was not statistically significant.

Outcomes	β (95% CI) Per SD increase	Tertile 1	Tertile 2	Tertile 3	P for trend
FBG					
Model 1	0.185 (0.120,0.251)	Reference	0.045 (0.008,0.083)	0.099 (0.061,0.137)	<0.001
Model 2	0.149 (0.087,0.211)	Reference	0.047 (0.012,0.083)	0.077 (0.041,0.113)	<0.001
Model 3	0.100 (0.040,0.160)	Reference	-0.025 (-0.008,0.059)	0.048 (0.014,0.082)	0.007
HOMAIR					
Model 1	0.580 (0.303,0.858)	Reference	0.120 (-0.039,0.279)	0.358 (0.198,0.518)	<0.001
Model 2	0.553 (0.274,0.831)	Reference	0.119 (-0.039,0.277)	0.342 (0.182,0.502)	<0.001
Model 3	0.273 (0.022,0.523)	Reference	-0.024 (-0.165,0.117)	0.165 (0.021,0.309)	0.014
FSI					
Model 1	2.047 (1.107,2.988)	Reference	0.382 (-0.156,0.920)	1.290 (0.750,1.831)	<0.001
Model 2	2.035 (1.093,2.977)	Reference	0.378 (-0.157,0.912)	1.288 (0.747,1.829)	<0.001
Model 3	1.042 (0.200,1.885)	Reference	-0.124 (-0.598,0.350)	0.658 (0.175,1.141)	0.003
HAb1c					
Model 1	0.043 (0.003,0.084)	Reference	-0.015 (-0.039,0.008)	0.031 (0.008,0.055)	0.003
Model 2	-0.0002 (-0.038,0.037)	Reference	-0.014 (-0.035,0.007)	0.002 (-0.019,0.024)	0.662
Model 3	-0.043 (-0.079,-0.006)	Reference	-0.028 (-0.049,-0.008)	-0.019 (-0.041,0.002)	0.132

TABLE 2 Coefficients (95% CI) for the relationship between the SII and the markers of T2D risk.

Relationship between SII and prediabetes

Table 4 presents the association between SII evaluated based on its tertiles and prediabetes. In Model 1, without adjusting for any factors, the relationship between continuous LgSII and prediabetes was significant (OR=1.60; 95% CI: 1.29-2.00; P<0.001). After adjusting for all potential covariates, an increase of 1 unit in SII score was associated with a 43% increased odds of having prediabetes (OR: 1.43; 95% CI: 1.13 to 1.82). Additionally, we assessed the relationship between tertiles of SII scores and prediabetes. Individuals with the highest SII tertile had a 17% increased odds of prediabetes compared to those in the lowest tertile (OR: 1.17; 95% CI: 1.02 to 1.34; P=0.029), whereas the association between the second SII tertile and prediabetes was not significant.

The multivariable logistic regression model

In the fully adjusted multivariable logistic regression model, age, race, smoking, alcohol consumption, physical activity, ALT, AST, alkaline phosphatase, BMI, triglycerides, and blood chloride levels still show significant associations with the odds of IR (Table 5). Factors significantly associated with the risk of prediabetes include age, gender, race, ALT, AST, BMI, TG, blood chloride levels, and LDH (Table 6). Compared to participants aged 18-39, those aged 40-59 have 2.45 times higher odds of prediabetes, while participants over 60 have 7.04 times higher odds of prediabetes (P<0.001), and a 35.5% higher risk of IR (P<0.001). Compared to Mexican-American individuals, non-Hispanic white individuals have a 27.8% lower likelihood of IR and a 28.2% lower likelihood of prediabetes (P<0.001), while non-Hispanic black individuals have a 24.3%

	Model 1		Model 2		Model 3	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Continuous LgSII	1.73 (1.45, 2.06)	<0.001	1.89 (1.57, 2.28)	<0.001	1.65 (1.32, 2.04)	<0.001
Tertile 1	Reference		Reference		Reference	
Tertile 2	1.14 (1.03, 1.26)	0.011	1.18 (1.06, 1.31)	0.002	1.04 (0.92, 1.18)	0.510
Tertile 3	1.40 (1.27, 1.55)	<0.001	1.47 (1.32, 1.63)	<0.001	1.34 (1.18, 1.51)	<0.001
P for trend	<0.001		<0.001		<0.001	

TABLE 3 The associations between SII and IR.

P value

0.003

0.865

0.029

P for trend

	Model 1		Model 2		Model 3	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	
Continuous LgSII	1.60 (1.29, 2.00)	<0.001	1.61(1.28,2.03)	<0.001	1.43 (1.13,1.82)	Γ
Tertile 1	Reference		Reference		Reference	
Tertile 2	1.01 (0.89, 1.15)	0.846	1.08 (0.95,1.24)	0.252	1.01 (0.88, 1.16)	
Tertile 3	1.26 (1.12, 1.43)	<0.001	1.26 (1.10,1.44)	<0.001	1.17 (1.02, 1.34)	

0.001

TABLE 4 The associations between SII and prediabetes.

< 0.001

higher risk of IR (P=0.02). Compared to smokers, non-smokers and former smokers have a 50.9% and 56.5% increased odds of IR, respectively (P<0.001).With each unit increase in TG and ALT, the odds of IR increase by 292.2% (P<0.001) and 26% (P<0.001), respectively, while the odds of prediabetes increase by 53.6% and 1% (both P<0.001). Compared to non-obese participants with a BMI less than 30, obese participants have 448% higher odds of IR and 99.8% higher odds of prediabetes (P<0.001).

Subgroup analysis

Our subgroup analysis reveals inconsistent associations between SII levels and IR as well as prediabetes (Figures 2, 3). In subgroups based on gender, race, and alcohol consumption, significant associations between SII and IR are detected in each subgroup (all P<0.05).However, among participants with prediabetes, only females, those aged 18-39, non-Hispanic white individuals, those with high school education or less, PIR<1 and 2<PIR<4, former or current smokers, drinkers, and physically active participants show statistically significant associations in subgroups stratified by gender, age, race, education, PIR, smoking status, alcohol consumption, and physical activity. Additionally, interaction tests show that age is the most prominent interacting factor influencing the relationship between SII and IR as well as prediabetes. For younger participants (18-39 years old), with increasing SII levels, the risk of both IR (OR=4.29, 95% CI: 3.11-5.92) and prediabetes (OR=5.78, 95% CI: 3.31-10.08) is significantly higher than in middle-aged participants (P<0.001). Among other factors, physical activity and gender are prominent factors influencing the relationship between SII and IR (P<0.05), and education level may influence the positive correlation between SII and prediabetes (P=0.045).

Analysis of restricted cubic spline regression

We further assessed the dose-response relationship between SII and prediabetes as well as IR using restricted cubic splines. In a model without adjusting for any covariates, we found a significant non-linear relationship between SII and prediabetes (P=0.017, Figure 4A), and the dose-response curve exhibits an inverted U shape. However, after adjusting for several covariates, the relationship between SII and prediabetes became linear (P>0.05) (Figures 4B, C). Additionally, irrespective of covariate adjustments, there is a linear dose-response relationship between SII scores and IR (Figures 4D–F).

0.019

Discussion

To our knowledge, this is the initial investigation assessing the association between SII and prediabetes in the adults of the United States. A recent study have reported a positive linear associations between higher SII and increased risk of IR, which is consistent with our findings. However, their study did not adequately exclude patients with existing diabetes or those taking medications that could affect IR, and our research included a higher number of study populations (23). Therefore, our research results are more reliable and more complete.

In this cross-sectional study involving American adults, we observed a significant correlation between elevated SII levels and risk markers for T2D (FBG, FSI, and HOMA-IR). Furthermore, after further adjusting for potential confounding factors, the association between SII and increased risk of IR and prediabetes persisted. However, the positive correlation between SII and IR or prediabetes is more significant in females than in males. Additionally, the restricted cubic spline model indicates a linear dose-response relationship between SII and the odds of IR and prediabetes. These findings suggest that SII may serve as a monitoring indicator for IR and prediabetes.

Zhao et al. illustrated that continuous SII exhibit a skewed distribution, aligning with the structure of our original data. To approximate it to a normal distribution, they recommended logarithmic transformation of SII (24). From Table 1, it can be seen that some traditional diabetes risk factors, such as older age, smoking, and higher BMI, are more likely to have higher SII values, while protective factors like MVPA are more likely to have lower SII values. Additionally, our study revealed a positive correlation between continuous SII and glycated hemoglobin. However, this correlation vanished after adjusting for confounding factors and categorizing SII into tertiles.

SII is a recognized indicator for predicting cancer treatment outcomes and prognosis. Apart from cancer, the predictive value of SII for other metabolic-related diseases, such as diabetes and TABLE 5 Multivariate logistic regression models of IR.

VariablesOR (95% Cl)P valueSII1.645 (1.324, 2.042) 0.001Age (versus 18-39 yeass)3.55 (1.162, 1.580)0.0012.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.602.60		-	
Age (versus 18-39 years			
40-591.074 (0.954, 1.208)0.23740-591.355 (1.162, 1.580)<.0011	-		<0.001
Note of the second se		ld)	
Prediction of the section of the se	40-59	1.074 (0.954, 1.208)	0.237
Race (versus Mexican AmericanRace (versus Mexican American0ther Hispanic0.957 (0.782, 1.170)0.668Non-Hispanic White0.722 (0.618, 0.845)<.0.01	>60	1.355 (1.162, 1.580)	<0.001
Other Hispanic 0.957 (0.782, 1.170) 0.668 Non-Hispanic White 0.722 (0.618, 0.845) 0.001 Non-Hispanic Black 1.239 (1.033, 1.487) 0.021 Other Races 0.901 (0.730, 1.112) 0.332 Education level (versus Levent High school 0.965 (0.832, 1.118) 0.635 More than high school 0.965 (0.837, 1.107) 0.593 Smoke (versus current servert 0.965 (0.832, 1.118) 0.601 Smoke (versus current servert 0.965 (0.832, 1.118) 0.601 Non-smoker 1.509 (1.316, 1.732) <0.001	Female (versus male)	0.904 (0.805, 1.015)	0.087
Non-Hispanic White0.722 (0.618, 0.845)<0001Non-Hispanic Black1.239 (1.033, 1.487)0.021Other Races0.901 (0.730, 1.112)0.332Education level (versus lextran high school0.965 (0.832, 1.118)0.635More than high school0.963 (0.837, 1.107)0.593More than high school0.963 (0.837, 1.107)0.593Smoke (versus current swert0.001Former smoker1.565 (1.340, 1.828)<0.001	Race (versus Mexican Ame	erican)	
Non-Hispanic Black1.239 (1.033, 1.487)0.021Other Races0.901 (0.730, 1.112)0.332Education level (versus Extan high school0.650 (0.832, 1.118)0.635More than high school0.963 (0.837, 1.107)0.593More than high school1.509 (1.316, 1.732)0.001Former smoker1.565 (1.340, 1.828)0.001MVPA (versus less physical activity)1.269 (1.127, 1.428)0.001Alcohol consumption (versus less than 12 drinks/year)0.945 (0.816, 1.094)0.033PIR (versus less than 12 drinks/year)0.945 (0.816, 1.094)0.4472.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6170.012.40.945 (0.816, 1.094)0.6100.012.40.945 (0.816, 1.094)0.6100.012.40.945 (0.816, 1.094)0.010.012.50.945 (0.916, 1.094)0.010.012.60.947 (0.916, 0.914)0.010.012.60.947 (0.916, 0.914)0.010.012.70.945 (0.916, 0.914)0.010.012.80.947 (0.916, 0.914)0.0120.01 <td>Other Hispanic</td> <td>0.957 (0.782, 1.170)</td> <td>0.668</td>	Other Hispanic	0.957 (0.782, 1.170)	0.668
Other Races0,901 (0,730, 1.112)0.332CHUCATION Level (versus Leven high school0.965 (0.832, 1.118)0.635High school diploma0.965 (0.832, 1.118)0.635More than high school0.963 (0.837, 1.107)0.593Smoke (versus current swern0.0010.593Smoker1.509 (1.316, 1.732)<0.001Former smoker1.565 (1.340, 1.828)<0.001MVPA (versus less physical activity)1.269 (1.127, 1.428)<0.001Alcohol consumption (versus less than 12 drinks/year)1.202 (1.066, 1.356)0.003PIR (versus less than 120.945 (0.816, 1.094)0.4471-20.945 (0.816, 1.094)0.4472-40.960 (0.826, 1.116)0.5972-40.960 (0.826, 1.116)0.1672-40.960 (0.826, 1.116)0.1672-40.960 (0.827, 0.104)0.1012-50.0010.1022-60.1120.0012-70.986 (0.979, 0.992)0.0012-80.482 (4.922, 6.107)0.0012-90.482 (4.922, 6.107)0.0012-100.797 (0.756, 0.840)0.0122-110.998 (0.996, 1.000)0.0122-120.998 (0.997, 0.021)0.0122-130.021 (0.021, 0.031)0.0122-140.998 (0.997, 0.020)0.0492-150.001 (0.999, 1.002)0.064	Non-Hispanic White	0.722 (0.618, 0.845)	<0.001
Education level (versus less than high school 0.965 (0.832, 1.118) 0.635 More than high school 0.963 (0.837, 1.107) 0.593 Smoke (versus current smoker) 0.001 Former smoker 1.509 (1.316, 1.732) <0.001	Non-Hispanic Black	1.239 (1.033, 1.487)	0.021
High school diploma 0.965 (0.832, 1.118) 0.635 More than high school 0.963 (0.837, 1.107) 0.593 Smoke (versus current swers) Smoke (versus current smoker 0.001 Non-smoker 1.509 (1.316, 1.732) <0.001	Other Races	0.901 (0.730, 1.112)	0.332
Advance Advance <t< td=""><td>Education level (versus les</td><td>ss than high school</td><td>)</td></t<>	Education level (versus les	ss than high school)
Smoke (versus current smoker) Non-smoker 1.509 (1.316, 1.732) <0.001	High school diploma	0.965 (0.832, 1.118)	0.635
Non-smoker 1.509 (1.316, 1.732) <0.001 Former smoker 1.565 (1.340, 1.828) <0.001	More than high school	0.963 (0.837, 1.107)	0.593
Former smoker 1.565 (1.340, 1.828) <0.001 MVPA (versus less physical activity) 1.269 (1.127, 1.428) <0.001	Smoke (versus current sm	oker)	
MVPA (versus less physical activity) 1.269 (1.127, 1.428) <0.001 Alcohol consumption (versus less than 12 drinks/year) 1.202 (1.066, 1.356) 0.003 PIR (versus less than 1) 0.945 (0.816, 1.094) 0.447 1-2 0.945 (0.816, 1.094) 0.447 2-4 0.960 (0.826, 1.116) 0.597 >4 0.892 (0.759, 1.049) 0.167 Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001	Non-smoker	1.509 (1.316, 1.732)	< 0.001
physical activity) 1.269 (1.127, 1.428) <0.001	Former smoker	1.565 (1.340, 1.828)	< 0.001
less than 12 drinks/year) 1.202 (1.066, 1.356) 0.003 PIR (versus less than 1) 0.945 (0.816, 1.094) 0.447 1-2 0.945 (0.816, 1.094) 0.597 >4 0.960 (0.826, 1.116) 0.597 >4 0.892 (0.759, 1.049) 0.167 Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001		1.269 (1.127, 1.428)	<0.001
1-2 0.945 (0.816, 1.094) 0.447 2-4 0.960 (0.826, 1.116) 0.597 >4 0.892 (0.759, 1.049) 0.167 Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001	*	1.202 (1.066, 1.356)	0.003
2-4 0.960 (0.826, 1.116) 0.597 >4 0.892 (0.759, 1.049) 0.167 Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001	PIR (versus less than 1)		
>4 0.892 (0.759, 1.049) 0.167 Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001	1-2	0.945 (0.816, 1.094)	0.447
Alkaline phosphotase (U/L) 1.004 (1.002, 1.006) <0.001 ALT (U/L) 1.026 (1.021, 1.031) <0.001	2-4	0.960 (0.826, 1.116)	0.597
ALT (U/L) 1.026 (1.021, 1.031) <0.001	>4	0.892 (0.759, 1.049)	0.167
AST (U/L) 0.986 (0.979, 0.992) <0.001	Alkaline phosphotase (U/L)	1.004 (1.002, 1.006)	<0.001
BMI (kg/m²) ≥30 5.482 (4.922, 6.107) <0.001	ALT (U/L)	1.026 (1.021, 1.031)	<0.001
≥30 5.482 (4.922, 6.107) <0.001	AST (U/L)	0.986 (0.979, 0.992)	<0.001
TC (mmol/L) 0.797 (0.756, 0.840) <0.001	BMI (kg/m ²)		
TG (mmol/L) 3.922 (3.519, 4.370) <0.001	≥30	5.482 (4.922, 6.107)	<0.001
Chloride (mmol/L) 1.024 (1.004, 1.043) 0.012 Creatinine (mol/L) 0.998 (0.996, 1.000) 0.049 Gamma glutamyl transferase (U/L) 1.000 (0.999, 1.002) 0.664	TC (mmol/L)	0.797 (0.756, 0.840)	<0.001
Creatinine (mol/L) 0.998 (0.996, 1.000) 0.049 Gamma glutamyl transferase (U/L) 1.000 (0.999, 1.002) 0.664	TG (mmol/L)	3.922 (3.519, 4.370)	<0.001
Gamma glutamyl transferase (U/L) 1.000 (0.999, 1.002) 0.664	Chloride (mmol/L)	1.024 (1.004, 1.043)	0.012
(U/L) 1.000 (0.999, 1.002) 0.664	Creatinine (mol/L)	0.998 (0.996, 1.000)	0.049
Lactate dehydrogenase (U/L) 0.998 (0.996, 1.000) 0.067	e ,	1.000 (0.999, 1.002)	0.664
	Lactate dehydrogenase (U/L)	0.998 (0.996, 1.000)	0.067

cardiovascular diseases, is also gaining attention (25, 26). The study by Nie et al. revealed an association between increased SII and increased prevalence of diabetes (27). Bian et al. found that CAD patients undergoing PCI with worse prognostic outcomes tended to have higher SII values (28). In a cross-sectional study conducted in

TABLE 6 Multivariate logistic regression models of prediabetes.

5	5	
Variables	OR (95% CI)	P value
SII	1.442 (1.136, 1.830)	0.003
Age (versus 18-39 years o	ld)	
40-59	3.451 (2.974, 4.006)	< 0.001
>60	7.041 (5.894, 8.411)	<0.001
Female (versus male)	0.625 (0.548, 0.711)	<0.001
Race (versus Mexican Ame	erican)	
Other Hispanic	0.880 (0.702, 1.104)	0.269
Non-Hispanic White	0.718 (0.603, 0.886)	<0.001
Non-Hispanic Black	1.233 (1.007, 1.509)	0.042
Other Races	0.907 (0.706, 1.165)	0.444
Education level (versus les	ss than high school))
High school diploma	0.992 (0.845, 1.164)	0.918
More than high school	0.847 (0.726, 0.988)	0.035
Smoke (versus current sm	oker)	
Non-smoker	0.890 (0.762, 1.038)	0.138
Former smoker	0.935 (0.790, 1.106)	0.431
MVPA (versus less physical activity)	1.024 (0.901, 1.164)	0.714
Alcohol consumption (versus less than 12drinks/year)	1.108 (0.967, 1.268)	0.140
PIR (versus less than 1)		
1-2	0.934 (0.793, 1.101)	0.419
2-4	0.937 (0.790, 1.113)	0.460
>4	0.900 (0.749, 1.083)	0.266
Alkaline phosphotase (U/L)	1.001 (0.999, 1.004)	0.360
ALT (U/L)	1.010 (1.005, 1.075)	<0.001
AST (U/L)	0.986 (0.980, 0.993)	<0.001
BMI (kg/m ²)		
≥30	1.988 (1.766, 2.237)	< 0.001
TC (mmol/L)	0.974 (0.921, 1.031)	0.368
TG (mmol/L)	1.536 (1.375, 1.715)	<0.001
Chloride (mmol/L)	0.963 (0.944, 0.982)	<0.001
Creatinine (µmol/L)	0.998 (0.996, 1.000)	0.061
Gamma glutamyl transferase (U/L)	1.001 (0.999, 1.002)	0.278
Lactate dehydrogenase (U/L)	1.004 (1.002, 1.006)	<0.001

the United States with 12,402 participants, a significant correlation between SII and metabolic syndrome was found after inclusion (24). Metabolic syndrome is a condition characterized by an aggregation of various metabolic risk factors related to IR and impaired glucose regulation (29). Inspired by this discovery, we focus on whether SII

Subgroups	OR (95% CI)	P value		P for interaction
MVPA				0.011
yes	2.25 (1.80, 2.80)	< 0.001		
no	1.21 (0.86, 1.72)	0.273	k-∎-1	
Smoke				0.067
current smoker	1.28 (0.87, 1.89)	0.215	⊬ ∎-1	
non-smoker	2.34 (1.81, 3.04)	< 0.001		
former smoker	1.84 (1.26, 2.70)	0.002	⊢-∎1	
PIR				0.114
>4	2.31 (1.58, 3.39)	< 0.001		
2-4	2.42 (1.67, 3.50)	< 0.001		
1-2	1.24 (0.88, 1.76)	0.220	⊬∎⊣	
<1	1.92 (1.28, 2.88)			
Alcohol consumption				0.180
yes	1.78 (1.43, 2.22)	< 0.001	H	0.100
no		< 0.001		
Age	2102 (1102, 0100)	01001		< 0.001
old age	1.07 (0.75, 1.54)	0.703	⊦⊧∎⊣	
middle age		0.033		
young age		< 0.001		
Education Level	(0.11, 0.02)	-0.001		0.115
More than high school	2.01 (1.54, 2.61)	< 0.001	⊢∎-4	01110
High school diploma		< 0.001		
Less than high school	1.45 (0.92, 2.13)		┝╼╴╵	
Races	1.15 (0.52, 2.15)	0.002	1	0.883
Other Races	2.31 (1.23, 4.41)	0.011		0.005
Non-Hispanic Black		0.001	│⊢∎	
Non-Hispanic White		< 0.001		
Other Hispanic		0.004		
Mexican American	1.66 (1.01, 2.74)			
Gender	1.00 (1.01, 2.74)	0.045		0.047
Female	2.56 (1.94, 3.37)	< 0.001		0.047
Male	1.47 (1.14, 1.90)			
Wate	1.47 (1.14, 1.90)	0.005		
		Г 0	2 4 6	8
		0	2 4 0	ð

Subgroups	OR (95% CI) P value	P for interaction
MVPA		0.760
yes	1.73 (1.31, 2.29) <0.001	
no	1.39 (0.93, 2.08) 0.114	
Smoke		0.086
current smoker	2.17 (1.34, 3.51) 0.002	01000
non-smoker	1.32 (0.95, 1.84) 0.099	
former smoker	1.97 (1.26, 3.06) 0.003	
PIR		0.099
>4	1.21 (0.76, 1.93) 0.419	
2-4	1.89 (1.18, 2.93) 0.008	
1-2	1.29 (0.85, 1.98) 0.236	
<1	2.57 (1.53, 4.32) <0.001	
Alcohol consumption		0.680
yes	1.64 (1.25, 2.16) <0.001	0.000
no	1.65 (1.06, 2.55) 0.026	
Age	1.05 (1.00, 2.55) 0.020	<0.001
old age	1.32 (0.90, 1.93) 0.155	-0.001
middle age	1.26 (0.90, 1.77) 0.186	
young age	5.78 (3.31, 10.08) <0.001	_
Education Level	5.76 (5.51, 10.06) 40.001	0.045
More than high school	1.69 (1.20, 2.36) 0.003	
High school diploma	1.11 (0.72, 1.71) 0.642	
Less than high school	2.36 (1.49, 3.74) <0.001	
Races	2.50 (115, 5171) 0.001	0.442
Other Races	1.02 (0.43, 2.45) 0.965	0.442
Non-Hispanic Black	1.36(0.84, 2.19) 0.214	
Non-Hispanic White	1.86 (1.33, 2.61) <0.001	
Other Hispanic	1.89 (0.81, 4.42) 0.141	
Mexican American	1.83 (0.98, 3.42) 0.058	
Gender	1.65 (0.96, 5.42) 0.656 1	0.061
Female	2.13 (1.48, 3.07) <0.001	0.001
Male	1.37 (1.02, 1.85) 0.039	
Iviale	1.57 (1.02, 1.05) 0.057	
	0 2 4	6 8




FIGURE 4

The dose-response relationships of SII with prediabetes (A–C) and IR (D–F) in Model 1 (unadjusted for any covariates), Model 2 (adjusted for covariates including age, gender, race, smoking and drinking status, PIR, education level, and physical activity status) and Model 3 (adjusted for age, gender, race, smoking and drinking status, PIR, education level, physical activity status, BMI, TC, TG, ALT, AST, γ-GGT, ALP, Cr, and LDH). Results were from restricted cubic spline models.

holds equal value in identifying and predicting IR and prediabetes. There are few studies that have independently evaluated the association between SII and IR as well as prediabetes. Numerous studies have indicated a significant association between SII and complications of diabetes.

In the work by Elbeyli, the SII was identified as a potential diagnostic biomarker for diabetic macular edema, with positive implications for improving diabetic retinopathy (30). Özata et al. further explored the correlation between SII and diabetic macular edema, revealing that an elevated SII level might lead to an increased incidence of serous retinal detachment (31). The research of Safak et al. unveiled the potential of SII as a predictive indicator for diabetic foot osteomyelitis (32). Moreover, in a survey of Indonesian diabetic patients, Yohanes and Andy found a significant association between low SII levels and the regulation of psychological well-being in diabetic patients (33).

In clinical studies, both IR and prediabetes have been found to be associated with several traditional inflammatory markers. Jia et al. used the rate nephelometry method to measure serum IMA and hs-CRP concentrations in patients with diabetic retinopathy, finding a positive correlation between hs-CRP concentration and the incidence of diabetic retinopathy (34). Liu et al. suggested that serum hs-CRP concentration can predict the incidence of diabetes (35). However, some studies have found no difference in the presence or absence of hs-CRP with IR. Systemic levels of TNF-a, IL-1b, IL-6, and CRP are elevated in both type 1 and type 2 diabetes patients (36, 37), which is a result of the chronic activation of proinflammatory pathways within insulin-target cells (38). Consequently, these cytokines and inflammatory mediators, especially TNF- α , monocyte chemoattractant protein-1 (MCP-1), CRP, and interleukins, are considered potential contributors to IR or impaired B-cell function (39). Additionally, in the study by Shu et al., it was found that the dietary inflammatory index is positively correlated with FBG, FSI, and HOMA-IR, and a more pro-inflammatory diet is associated with increased odds of IR and prediabetes (40).

In recent years, an increasing number of studies have focused on the significance of common inflammatory markers in blood routine examinations in the diagnosis and treatment of metabolic diseases. Additionally, Christine Lee and colleagues investigated the relationship between various white blood cell subtypes and IR in high-risk individuals, finding a positive correlation with all white blood cell subtypes, including granulocytes, lymphocytes, and monocytes (41). Karakaya studied 96 obese patients and 40 healthy controls, discovering a positive correlation between IR and white blood cell count, with NLR higher in obese IR patients than non-IR obese patients (42). Rodríguez-Rodríguez et al. also found a similar phenomenon in children (43). Some studies suggest that participants resistant to insulin have significantly higher platelet counts than insulin-sensitive participants (44). Hwang et al. found that with an increase in platelet count, the incidence of diabetes also increased, indicating that platelets are a potential risk marker (11). However, in the study by Rodríguez-Rodríguez, it was found that high platelet values do not constitute a risk factor for the occurrence of IR in children, and no relationship was observed between IR and PLR (43). In related reports, it seems that NLR is

better at predicting inflammation than PLR, as neutrophils play a dominant role in inflammation by releasing vasoactive and cytotoxic substances (such as reactive oxygen species and digestive enzymes) during inflammation, leading to increased endothelial permeability (45). Therefore, it is necessary to introduce a more accurate SII index that includes platelet count for further research.

In various studies on inflammatory markers, SII, with its advantage of integrating three key immune cells, provides a more comprehensive description of the body's inflammatory state compared to traditional single inflammatory biomarkers. For instance, Berbudi et al. revealed that SII, in predicting the impact of T2D on the immune system, demonstrates more precise and effective predictive capability than NLR, PLR, and MLR, as significantly confirmed by ROC curve analysis (46). Furthermore, the study by Nicoară's team confirms that, in differentiating whether obese children have metabolic syndrome, SII exhibits higher diagnostic efficacy compared to NLR, PLR, and SIRI. It also shows a positive correlation with the HOMA-IR (47). These findings offer a new perspective for clinically assessing inflammatory and metabolic abnormal states.

The primary strength of this study is the inclusion of a large number of samples. Based on NHANES database, we analyzed a total of 9250 samples from 2005 to 2018, including self-reports, laboratory tests, and physical examinations. These data were collected by professionals through a standardized procedure, significantly reducing errors caused by different methods. The enormous sample size and standardized data contribute to obtaining meaningful and highly reliable results even after multiple condition screenings. And this study not only screened diabetic patients based on fasting blood glucose level >7.0 mmol/L but also excluded potential diabetic patients based on medication use and HbA1c levels. Additionally, to explore the impact of confounding factors on the association between SII and IR and prediabetes, we conducted stratified analyses. The results revealed that factors such as age, gender, race, education level, and family income-poverty ratio had some impact on the incidence of IR and prediabetes. For example, older patients have higher SII values and are at higher risk for IR and prediabetes. And our results show that women are more likely to have higher SII values than men, suggesting that they are more likely to have IR as well as prediabetes. Furthermore, lifestyle factors such as smoking, more alcohol consumption, and lower physical activity level were also positively associated with the risk of developing IR and prediabetes. Finally, we used non-restrictive cubic spline plots to analyze the nonlinear relationship between SII and IR and prediabetes, providing a more comprehensive understanding of their development and risk factors.

However, this study has certain limitations. Firstly, the nature of observational research restricts our analysis of causal relationships, leaving room for multiple interpretations, including both causation and reverse causation. Therefore, prospective studies are urgently needed to clarify the precise connections among these factors. Additionally, despite adjusting for various covariates, potential confounding factors such as dietary patterns and a family history of T2D might still be overlooked. It's worth noting that, although diet has a significant impact on circulating TG levels, fasting blood samples collected in this study may not fully capture this aspect. Future research should delve into exploring the specific influence of dietary factors on study results.

Despite some limitations and drawbacks, our study still holds significant clinical relevance. As a novel inflammatory biomarker, SII not only offers the advantage of non-invasiveness but also provides a more comprehensive approach to assessing immune and inflammatory responses. The results of this study confirm our previous hypothesis that SII can serve as crucial indicators for diagnosing IR and prediabetes. In an era where IR is prevalent, often elusive, and troubling to primary care communities, the SII scoring system, comprising three simple and efficient hematological indicators, provides a practical diagnostic tool for primary healthcare practitioners. In the future, we plan to initiate a multicenter prospective cohort study to explore the effectiveness of SII as an independent predictor of IR and prediabetes. The goal is to offer prospective guidance and intervention for high-risk individuals through routine blood cell count monitoring, aiming for prevention and protection.

Conclusion

In conclusion, this study indicates a positive correlation between SII and FBG, FSI, and HOMA-IR, so higher SII levels may increase the odds of IR and prediabetes. Therefore, SII is poised to be a direct and cost-effective method for identifying patients with IR and prediabetes.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.cdc.gov/nchs/nhanes/.

Ethics statement

The studies involving humans were approved by National Center for Health Statistics. The studies were conducted in accordance with the local legislation and institutional requirements. The human samples used in this study were acquired from gifted from another research group. Written informed consent for participation was not required from the participants or the participants' legal guardians/next of kin in accordance with the national legislation and institutional requirements. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HG: Writing – original draft, Validation, Methodology, Data curation. CW: Writing – original draft, Methodology. JZ: Writing – original draft. XJ: Writing – review & editing, Project administration. SL: Writing – review & editing, Supervision, Conceptualization.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Natural Science Foundation of China (NSFC No. 81570694).

References

1. Xu NY, Nguyen KT, DuBord AY, Pickup J, Sherr JL, Teymourian H, et al. Diabetes technology meeting 2021. J Diabetes Sci Technol. (2022) 16:1016–56. doi: 10.1177/19322968221090279

2. Association AD. Economic costs of diabetes in the U.S. @ in 2012. Diabetes Care. (2013) 36:1033–46. doi: 10.2337/dc12-2625

3. Brunetti A, Chiefari E, Foti D. Recent advances in the molecular genetics of type 2 diabetes mellitus. *World J Diabetes*. (2014) 5:128–40. doi: 10.4239/wjd.v5.i2.128

4. Rudvik A, Månsson M. Evaluation of surrogate measures of insulin sensitivity - correlation with gold standard is not enough. *BMC Med Res Methodol*. (2018) 18:64. doi: 10.1186/s12874-018-0521-y

5. Mirabelli M, Chiefari E, Arcidiacono B, Corigliano DM, Brunetti FS, Maggisano V, et al. Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases. *Nutrients.* (2020) 12:1066. doi: 10.3390/nu12041066

6. Weaver JR, Odanga JJ, Breathwaite EK, Treadwell ML, Murchinson AC, Walters G, et al. An increase in inflammation and islet dysfunction is a feature of prediabetes. *Diabetes Metab Res Rev.* (2021) 37:e3405. doi: 10.1002/dmrr.3405

7. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. *Immunity*. (2022) 55:31–55. doi: 10.1016/j.immuni.2021.12.013

8. Daryabor G, Kabelitz D, Kalantar K. An update on immune dysregulation in obesityrelated insulin resistance. *Scand J Immunol.* (2019) 89:e12747. doi: 10.1111/sji.12747

9. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. *Nat Med.* (2009) 15:914–20. doi: 10.1038/nm.1964

10. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* (2014) 20:6212–22. doi: 10.1158/1078-0432.CCR-14-0442

11. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. *Sci Rep.* (2019) 9:3284. doi: 10.1038/s41598-019-39150-0

12. Chien TM, Li CC, Lu YM, Chou YH, Chang HW, Wu WJ. The predictive value of systemic immune-inflammation index on bladder recurrence on upper tract urothelial carcinoma outcomes after radical nephroureterectomy. *J Clin Med.* (2021) 10:5273. doi: 10.21203/rs.3.rs-829449/v1

13. Xu H, Feng H, Zhang W, Wei F, Zhou L, Liu L, et al. Prediction of immunerelated adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. *Exp Cell Res.* (2022) 416:113157. doi: 10.1016/j.yexcr.2022.113157

14. Chen JH, Zhai ET, Yuan YJ, Wu KM, Xu JB, Peng JJ, et al. Systemic immuneinflammation index for predicting prognosis of colorectal cancer. *World J Gastroenterol.* (2017) 23:6261–72. doi: 10.3748/wjg.v23.i34.6261

15. He K, Si L, Pan X, Sun L, Wang Y, Lu J, et al. Preoperative systemic immuneinflammation index (SII) as a superior predictor of long-term survival outcome in patients with stage I-II gastric cancer after radical surgery. *Front Oncol.* (2022) 12:829689. doi: 10.3389/fonc.2022.829689

16. Yang YL, Wu CH, Hsu PF, Chen SC, Huang SS, Chan WL, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. *Eur J Clin Invest.* (2020) 50:e13230. doi: 10.1111/eci.13230

17. Wang J, Zhou D, Dai Z, Li X. Association between systemic immuneinflammation index and diabetic depression. *Clin Interv Aging*. (2021) 16:97–105. doi: 10.2147/CIA.S285000

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

18. Guo W, Song Y, Sun Y, Du H, Cai Y, You Q, et al. Systemic immuneinflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018. *Front Endocrinol (Lausanne)*. (2022) 13:1071465. doi: 10.3389/fendo.2022.1071465

19. Song Y, Guo W, Li Z, Guo D, Li Z, Li Y. Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018. *Front Immunol.* (2022) 13:1058779. doi: 10.3389/fimmu.2022.1058779

20. Zhang J, Jiang J, Qin Y, Zhang Y, Wu Y, Xu H. Systemic immune-inflammation index is associated with decreased bone mass density and osteoporosis in postmenopausal women but not in premenopausal women. *Endocr Connect.* (2023) 12:e220461. doi: 10.1530/EC-22-0461

21. Ahmad T, Ismail A, Ahmad SA, Khalil KA, Kumar Y, Adeyemi KD, et al. Recent advances on the role of process variables affecting gelatin yield and characteristics with special reference to enzymatic extraction: A review. *Food Hydrocolloids*. (2017) 63:85–96. doi: 10.1016/j.foodhyd.2016.08.007

 Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, et al. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. *Ann Surg.* (2021) 273:532–41. doi: 10.1097/ SLA.000000000003370

23. Deng X, Liu D, Li M, He J, Fu Y. Association between systemic immuneinflammation index and insulin resistance and mortality. *Sci Rep.* (2024) 14:2013. doi: 10.1038/s41598-024-51878-y

24. Zhao Y, Shao W, Zhu Q, Zhang R, Sun T, Wang B, et al. Association between systemic immune-inflammation index and metabolic syndrome and its components: results from the National Health and Nutrition Examination Survey 2011-2016. *J Transl Med.* (2023) 21:691. doi: 10.1186/s12967-023-04491-y

25. Fan W, Zhang Y, Gao X, Liu Y, Shi F, Liu J, et al. The prognostic value of a derived neutrophil-lymphocyte ratio in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Clin Appl Thromb Hemost.* (2021) 27:10760296211034579. doi: 10.1177/10760296211034579

26. Kelesoglu S, Yilmaz Y, Elcık D, Kalay N. Systemic immune inflammation index: a novel predictor for coronary collateral circulation. *Perfusion*. (2022) 37:605–12. doi: 10.1177/02676591211014822

27. Nie Y, Zhou H, Wang J, Kan H. Association between systemic immuneinflammation index and diabetes: a population-based study from the NHANES. *Front Endocrinol (Lausanne).* (2023) 14:1245199. doi: 10.3389/fendo.2023.1245199

28. Bian X, He J, Zhang R, Yuan S, Dou K. The combined effect of systemic immuneinflammation index and type 2 diabetes mellitus on the prognosis of patients undergoing percutaneous coronary intervention: A large-scale cohort study. *J Inflammation Res.* (2023) 16:6415–29. doi: 10.2147/JIR.S445479

29. DeBoer MD. Assessing and managing the metabolic syndrome in children and adolescents. *Nutrients*. (2019) 11:1788. doi: 10.3390/nu11081788

30. Elbeyli A, Kurtul BE, Ozcan SC, Ozarslan Ozcan D. The diagnostic value of systemic immune-inflammation index in diabetic macular oedema. *Clin Exp Optom.* (2022) 105:831–5. doi: 10.1080/08164622.2021.1994337

31. Özata Gündoğdu K, Doğan E, Çelik E, Alagöz G. Serum inflammatory marker levels in serous macular detachment secondary to diabetic macular edema. *Eur J Ophthalmol.* (2022) 32:3637–43. doi: 10.1177/11206721221083465

32. Ozer Balin S, Ozcan EC, Uğur K. A new inflammatory marker of clinical and diagnostic importance in diabetic foot infection: systemic immune-inflammation index. *Int J Low Extrem Wounds*. (2022). doi: 10.1177/15347346221130817

33. Rias YA, Tsai HT, Thato R, Apriyanto BS, Chou KR, Ho SC, et al. Synergistic interactions of insufficient physical activity and a high systemic immune-inflammation index on psychological problems in Indonesians with type 2 diabetes mellitus. *Biol Res Nurs.* (2023) 25:516–26. doi: 10.1177/10998004231162050

34. Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. *Zhonghua Yan Ke Za Zhi.* (2009) 45:805–8.

35. Liu HH, Zhao D, Wang W, Qin LP, Liu J, Sun JY, et al. Association between high sensitivity C-reactive protein levels in serum and the 5-year-accumulative-risk of diabetes. *Zhonghua Liu Xing Bing Xue Za Zhi*. (2011) 32:1–4.

36. Kim CS, Park HS, Kawada T, Kim JH, Lim D, Hubbard NE, et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. *Int J Obes (Lond).* (2006) 30:1347–55. doi: 10.1038/ sj.ijo.0803259

37. Kato K, Otsuka T, Saiki Y, Kobayashi N, Nakamura T, Kon Y, et al. Association between elevated C-reactive protein levels and prediabetes in adults, particularly impaired glucose tolerance. *Can J Diabetes.* (2019) 43:40–5.e2. doi: 10.1016/j.jcjd.2018.03.007

38. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. *Annu Rev Physiol*. (2010) 72:219–46. doi: 10.1146/annurev-physiol-021909-135846

39. Yaribeygi H, Farrokhi FR, Butler AE, Sahebkar A. Insulin resistance: Review of the underlying molecular mechanisms. *J Cell Physiol.* (2019) 234:8152–61. doi: 10.1002/ jcp.27603

40. Shu Y, Wu X, Wang J, Ma X, Li H, Xiang Y. Associations of dietary inflammatory index with prediabetes and insulin resistance. *Front Endocrinol (Lausanne)*. (2022) 13:820932. doi: 10.3389/fendo.2022.820932

41. Lee CT, Harris SB, Retnakaran R, Gerstein HC, Perkins BA, Zinman B, et al. White blood cell subtypes, insulin resistance and β -cell dysfunction in high-risk individuals-the PROMISE cohort. *Clin Endocrinol (Oxf)*. (2014) 81:536–41. doi: 10.1111/cen.12390

42. Karakaya S, Altay M, Kaplan Efe F, Karadağ İ, Ünsal O, Bulur O, et al. The neutrophil-lymphocyte ratio and its relationship with insulin resistance in obesity. *Turk J Med Sci.* (2019) 49:245–8. doi: 10.3906/medical

43. Rodríguez-Rodríguez E, Salas-González MD, Ortega RM, López-Sobaler AM. Leukocytes and neutrophil-lymphocyte ratio as indicators of insulin resistance in overweight/obese school-children. *Front Nutr.* (2021) 8:811081. doi: 10.3389/fnut.2021.811081

44. Chen LK, Lin MH, Chen ZJ, Hwang SJ, Chiou ST. Association of insulin resistance and hematologic parameters: study of a middle-aged and elderly Chinese population in Taiwan. *J Chin Med Assoc.* (2006) 69:248–53. doi: 10.1016/S1726-4901 (09)70251-5

45. Boueiz A, Hassoun PM. Regulation of endothelial barrier function by reactive oxygen and nitrogen species. *Microvasc Res.* (2009) 77:26-34. doi: 10.1016/j.mvr.2008.10.005

46. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. *Curr Diabetes Rev.* (2020) 16:442–9. doi: 10.2174/ 1573399815666191024085838

47. Nicoară DM, Munteanu AI, Scutca AC, Mang N, Juganaru I, Brad GF, et al. Assessing the relationship between systemic immune-inflammation index and metabolic syndrome in children with obesity. *Int J Mol Sci.* (2023) 24:8414. doi: 10.3390/ijms24098414